Morning Stock Focus List for Tuesday, March 14, 2006: Submitting to the U.S. Food and Drug Administration! NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.
WESTON, FL -- (MARKET WIRE) -- 03/14/06 -- ************* names the following stocks to its Stock Focus List: Xechem International Inc. (OTC BB: XKEM), NMT Medical, Inc. (NASDAQ: NMTI), The Medicines Company (NASDAQ: MDCO), Google Inc. (NASDAQ: GOOG).
Xechem International, Inc. (OTC BB: XKEM) just announced that it has submitted its Orphan Drug Application for the five-membered heterocyclic anti-sickling compound known as 5-HMF to the United States Food and Drug Administration (FDA).
As reported on December 9, 2005, this promising compound has shown excellent biological activity in preliminary testing as an anti-sickling agent. If granted, Orphan Drug status will afford Xechem seven years of marketing exclusivity for the drug once the drug is ultimately approved by the FDA, and will offer Xechem tax credits, filing fee waivers and certain other statutory benefits.
Other stocks highlighted include NMT Medical, Inc. (NASDAQ: NMTI): Stock Focus List, down 33% on 9 million shares, The Medicines Company (NASDAQ: MDCO): Stock Focus List, up 10% on 5 million shares, Google Inc. (NASDAQ: GOOG): Stock Focus List, down 1% on 15 million shares.
"A few disappointing earnings releases and some disparate economic data have done their part to stall the market's advance, and political developments abroad have kept investors cautious. But overall tame inflation numbers, though rising over the past few months, solid growth in the domestic economy, and lower unemployment are buffeting the averages from below." More is available at: http://www.*************.
*************'s Daily Stock Updates:
*************, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.*************.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.************* or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated thirty thousand dollars for XKEM. CRG was compensated one hundred twenty thousand dollars in past compensation for XKEM. CRG intends to sell its shares. CRG has sold approximately zero XKEM shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
posted
Suprised on such big news this isn't moving that quick. I jumped in on the open not to miss the boat now my screen is all red. I think I just need to step away from the screen. I have sat back and watched this stock do some incredible things with no real news behind it. I can't imagine what it will do with todays news.
IP: Logged |
posted
This downward pressure is getting old. Just a matter of time before the good news eariler in the day finally registers and pops us up either EOD or tommorrow morning.
IP: Logged |
posted
Imaka: History does back that up. I know I have sold this short before and kicked myslef for it. Holding on, just expected a stronger day with such strong news the the AM.
IP: Logged |
posted
Today did turn out to be not the greatest, but it looks like most of the picks got pounded today thanks to the MMs. Lets just hope for a turnaround tomorrow. It's very likly that todays news will convert into big gains tomorrow. We'll see.
IP: Logged |
posted
it's the same story everyday. People always think tomorrow will be better. It will be better when there is serious news. Until then it will have it's little ups and downs.
-------------------- corn oil comes from corn, olive oil from olives, where does baby oil come from?
IP: Logged |
posted
Pandey represents XKEM Nigeria 21st March Tuesday at 10.00am Nigerian Products After him General Director of NAFDAC who aproved the drug speaks in the conference.
Markets Stocks Funds Bonds ETFs ****************: Issues Updates on Xechem International Incorporated
By M2 Last Update: 3/15/2006 11:09:53 AM Data provided by
Mar 15, 2006 (M2 PRESSWIRE via COMTEX) -- Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Today's activity on the OTC exchange has brought Xechem International Incorporated (XKEM) to the attention of our research team. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer. Shares of Xechem International Incorporated slipped 5% today to $.016 while trading 22 million at the time of publication. Although the company has not released any press today, the recent activity could be a carry over from yesterday's news.
Xechem International announced yesterday that it has submitted its Orphan Drug Application for the five-membered heterocyclic anti-sickling compound known as 5-HMF to the United States Food and Drug Administration (FDA).
As reported on December 9, 2005, this promising compound has shown excellent biological activity in preliminary testing as an anti-sickling agent. This was discovered by Prof. Donald Abraham and his team of scientists from Virginia Commonwealth University (VCU), Richmond, VA in collaboration with a team of doctors and scientists at NHLBI Sickle Cell Disease Reference Laboratory at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania led by Professor Toshio Asakura. Xechem has acquired the exclusive, worldwide rights from VCU for the production, sales and marketing of 5-HMF for use in the battle against SCD.
Research has shown that the 5-HMF compound is not only a natural product with very little if any toxicity, it also appears to be an effective anti-sickling agent which has shown high affinity for hemoglobin and is very active in genetically modified transgenic (Tg) mice. Professor Abraham of VCU has characterized this compound as "the best potential antisickling agent in 30 years research to be discovered by (VCU's) research group." See Xechem's December 9, 2005 Press Release.
If granted, Orphan Drug status will afford Xechem seven years of marketing exclusivity for the drug once the drug is ultimately approved by the FDA, and will offer Xechem tax credits, filing fee waivers and certain other statutory benefits.
According to Xechem's Chairman and CEO, Dr. Ramesh C. Pandey, "This new compound licensed from VCU represents the latest effort undertaken by Xechem in the fight against Sickle Cell Disease (SCD), and adds to Xechem's existing arsenal of NICOSAN(TM)/HEMOXIN(TM), an all natural, phyto-pharmaceutical product that has shown enormous promise for SCD sufferers. NICOSAN(TM)/HEMOXIN(TM) has already been designated as an Orphan Drug both in the United States and in European Union countries. It was acquired under an exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Government of Nigeria, Between the progress we have been making in bringing NICOSAN(TM) to market, and this exciting new heterocyclic pharmaceutical agent being developed in collaboration with VCU, we expect Xechem to be front and center in eventually offering the most viable and efficacious treatments to patients suffering with SCD around the world." Dr. Pandey added that the Company intends shortly to prepare and file an Investigational New Drug (IND) Application for submission to the FDA for both HEMOXIN(TM) and 5-HMF
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
